Fabtech Techn.

    544332
    Capital Goods·17 Nov 2025
    Management Summary

    Fabtech Technologies Cleanrooms Limited reported a challenging H1 FY26 with subdued standalone financials, as revenue and profit declined due to a strategic focus on reference creation and market penetration in new sectors. The company experienced margin compression and lost significant projects to competition. However, Fabtech demonstrated strong order inflow in the latter part of Q2, building a consolidated order book of 168 crores and a robust pipeline. With planned capacity expansions and a target of 30-40% revenue growth, management anticipates normalized margins and improved performance from FY27.

    Highlights5
    • Consolidated order book stands at 168 crores, with a balanced 50-50 mix between pharma and non-pharma.
    • Strong pipeline of 800 crores active leads, with 225 crores being 'very hot'.
    • Closed 110 crores worth of projects in the last 45 days of Q2 FY26, reflecting client confidence.
    • Kelvin subsidiary achieved 26 crore revenue and 1.62 crore PAT in H1 FY26, on track for 80 crore full-year revenue.
    • Capacity addition of 100-120 crores expected by Q1 FY27, tripling current capacity.
    Concerns Noted5
    • FTCL stand-alone revenue declined to 50 crores in H1 FY26 from 57 crores last year.
    • FTCL stand-alone profit declined to 2.9 crores in H1 FY26 from 5.1 crores last year.
    • H1 FY26 margins were around 6.5% (excluding other income), down from 10-10.5% due to reference creation strategy and one-time expenses.
    • Lost 208 crores of business due to marginal price differences and an internal 'moonlighting problem'.
    • Altair subsidiary incurred a 70 lakh loss, impacting the consolidated balance sheet.
    What Changed2

    vs Q4 FY26

    Guidance items5 → 7 (+2)Risks discussed4 → 6 (+2)
    Numbers6

    Key Financials

    MetricValueYoY
    FTCL Standalone Revenue₹50 Cr-12.3% YoY
    FTCL Standalone Profit₹2.9 Cr-43.1% YoY
    EBITDA Margin (H1 FY26)6.5%
    Kelvin Revenue (H1 FY26)₹26 Cr
    Kelvin PAT (H1 FY26)₹1.62 Cr
    Altair Loss (H1 FY26)₹0.7 Cr

    Segment Breakdown

    Share of Revenue

    • Pharma (FTCL Standalone)65.8%
    • Non-Pharma (Kelvin)34.2%
    Pharma (FTCL Standalone)
    ₹50 Cr Revenue0.6579% Share of Total Revenue
    Non-Pharma (Kelvin)
    ₹26 Cr Revenue0.3421% Share of Total Revenue

    Order Book

    high confidence

    Total Value

    ₹ 168 crores

    as of 2025-09-30

    quantified

    Inflow this qtr

    ₹ 110 crores

    Execution

    Pharma projects typically take 6-9 months, while non-pharma projects take 4-6 months.

    Composition

    Pharma(segment)
    50.0%
    Non-Pharma(segment)
    50.0%

    Pipeline

    deal pipeline tcv

    Strong active leads, with a significant portion being 'very hot'.

    Cancellations / Deferrals

    • other:Lost big-ticket projects due to marginal price differences.

    "The company is building a strong order book and pipeline, focusing on reference creation in new sectors, despite initial margin pressure."

    Source:
    Prepared remarks
    Capital7

    Capital Allocation

    high confidence
    CategoryHeadline
    Capex

    ₹100 crores

    Debt

    Debt disclosed

    M&A

    Aart Integrated Projects Private Limited

    Other · integrated

    M&A

    Kelvin Air Conditioning & Ventilation Systems Private Limited

    Other · integrated

    M&A

    Altair

    Other · integrated

    Promises7

    Guidance & Targets

    CategoryTargetPriority
    Revenue
    Revenue Growth30-40%
    High
    Revenue
    Revenue Growth40%
    High
    Revenue
    Kelvin Full Year Revenue80 crores
    High
    Order Book
    Order Book Position200-250 crores
    High
    Profitability
    PAT Margin7-8%
    Medium
    Capacity
    Capacity Addition100-120 crores
    High
    Market Share
    Market Share in Cleanrooms20%
    Medium
    Watchlist5

    Watch for Next Quarter

    #Metric
    01Kelvin PAT for stake increase
    02New Hyderabad unit operationalization
    03Order book position
    04Normalized PAT margins
    05Trade receivables reduction
    Risks6

    Risks & Concerns

    SeverityRisk
    medium

    Internal moonlighting problem

    A deep dive into project losses revealed a moonlighting problem, leading to employee terminations and tightened controls.

    Management
    medium

    Loss of big-ticket projects to competition

    Lost 208 crores of business due to marginal price differences, indicating intense competition.

    Management
    low

    Delayed pharma projects due to tariff war

    Some pharma projects were delayed due to ongoing tariff wars, impacting execution pace.

    Management
    low

    Labour shortages

    Faced issues with severe labour shortages, though management claims to have cracked the issue.

    Management
    medium

    Underperformance of subsidiary (Altair)

    Altair's 70 lakh loss impacted the consolidated balance sheet, and its performance is slower than expected.

    Management
    medium

    Competition from Japanese and Chinese imports

    The company is competing with established Japanese and Chinese players, requiring strategic pricing and PLI qualification efforts.

    Management
    Q&A8

    Q&A Highlights

    Narrative2m

    Detailed Narrative

    6 chapters
    01

    Strategic Inflection Year and Reference Creation

    Fabtech Technologies Cleanrooms Limited designated H1 FY26 as an 'inflection year,' prioritizing growth and reference creation across new sectors such as solar, data centers, and semi-cons. This strategic shift involved making business decisions over short-term commercial gains, resulting in a temporary margin compression to 6.5% from the previous 10-10.5%. Despite this, the company successfully closed 110 crores worth of projects in the last 45 days of Q2, signaling growing client confidence in its capabilities.

    02

    Robust Order Book and Pipeline Visibility

    The company's consolidated order book stands at 168 crores, evenly split with a 50-50 mix between pharma and non-pharma segments. Fabtech also boasts a strong pipeline of 800 crores in active leads, with 225 crores identified as 'very hot' and nearing final stages. Management projects an order book of 200-250 crores by March 2026, with execution timelines for projects ranging from 4-6 months for non-pharma and 6-9 months for pharma.

    03

    Significant Capacity Expansion Initiatives

    To support its ambitious growth targets, Fabtech is undertaking substantial capacity expansion, aiming to add 100-120 crores in capacity by Q1 FY27. This includes the procurement and installation of two new roll forming machines and an automatic panel assembly line. Additionally, the company is establishing a new manufacturing unit in Hyderabad, which will further enhance its production capabilities. Current capacity utilization is reported at approximately 60%.

    04

    Subsidiary Performance and Strategic Investments

    Kelvin, a key subsidiary, contributed 26 crores in revenue and 1.62 crores in PAT during H1 FY26, and is on track to achieve an 80 crore full-year revenue for FY26. Fabtech's 28% investment in Aart has proven valuable for technical expertise in solar and semi-con cleanrooms. While Advantek (26% stake) and Altair (80% stake) are progressing slower than expected, with Altair incurring a 70 lakh loss, management plans to increase its stake in Kelvin from 51% to 76% once Kelvin achieves a PAT of 7 crores.

    05

    Market Penetration and Competitive Strategy

    Fabtech is aggressively expanding into non-pharma sectors, securing significant projects in solar (e.g., Sangam Solar, Gopin Solar), data centers (Nextra, NSE), and electronics. The company is developing import-substitute T-grids, securing a 20 crore order for a solar company, and is actively pursuing PLI qualification with government ministries to enhance its competitive position against Japanese and Chinese imports. This strategy aims to leverage local manufacturing and execution capabilities.

    06

    Working Capital and Liquidity Management

    The company maintains banking limits of ₹22 crore, with minimal utilization, and has secured an additional ₹15 crore sanction, bringing total limits to ₹30-35 crore. While consolidated trade receivables increased from 53 crores in March 2025 to 65 crores in September 2025, management is committed to reducing this to within three months of total turnover by the year-end. This focus on working capital optimization is crucial for managing cash flow in long-cycle projects.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.